Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story-Reference-Cited by-同舟云学术

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story

Published:2022-04-07 Issue:7 Volume:6 Page:2331-2333
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Barosi Giovanni¹^ORCID,Gale Robert Peter²

Affiliation:

1. General Medicine 2, Center for the Study of Myelofibrosis, Policlinico S. Matteo Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy; and

2. Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/7/2331/1887224/advancesadv2022007230.pdf

Reference18 articles.

1. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study;Guglielmelli;Blood Adv.,2022

2. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med.,2012

3. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I;Verstovsek;Haematologica.,2013

4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med.,2012

5. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis;Cervantes;Blood.,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Methodological challenges in the development of endpoints for myelofibrosis clinical trials;The Lancet Haematology;2024-05

2. Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation;European Journal of Haematology;2024-02-09

3. New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors;American Journal of Hematology;2024-02-08

4. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

5. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices;American Journal of Hematology;2024-01-02